Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

Markets & Finance

First Albany Reiterates Buy on Adolor


First Albany reiterated its buy recommendation on shares of Adolor (ADLR).

Analyst David Webber says Adolor, at a recent recent "road show" presentation, reaffirmed its intent to complete submission of a New Drug Application for Entereg for postoperative ileus by June 30. He says that given the mixed nature of the Phase III data, the company's stragegy is to seek approval first for all abdominal surgery patients, to adjust to FDA resistance by seeking approval for just bowel resection patients or, if necessary, to amend the New Drug Application with an ongoing, large European ileus trial, due to conclude by the end of 2004. Assuming a 2007 launch for Entereg from a conservative point of view, the analyst has a $20 price target, based on his $1.86 2009 EPS forecast.


LIMITED-TIME OFFER SUBSCRIBE NOW
 
blog comments powered by Disqus